Zdrowie i gospodarka · 09/03/2016

FDA to Hold Public Hearing on Generic Drug Regulatory Science Initiatives and Request for Comments

The Food and Drug Administration (FDA) is hosting a public hearing to gather input from various stakeholders on research priorities for generic drugs, as part of its commitment to develop an annual list of regulatory science initiatives under the Generic Drug User Fee Amendments of 2012 (GDUFA). The hearing will inform the development of the FY 2017 Regulatory Science Plan.